←Back to Expert Scholars
Translational Medicine / 转化医学HER2 Ultra-Low
Ian Krop
MD, PhD
🏢Yale Cancer Center🌐USA
Associate Cancer Center Director
75
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Ian Krop contributed to the pivotal development of trastuzumab deruxtecan across the DESTINY-Breast program. His translational research clarifies HER2 heterogeneity and ADC bystander effects. He now leads clinical research at Yale Cancer Center.
Share:
🧪Research Fields 研究领域
HER2 ADCs
Trastuzumab deruxtecan
DESTINY-Breast trials
CNS metastases
Breast cancer translational
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Ian Krop 的研究动态
Follow Ian Krop's research updates
留下邮箱，当我们发布与 Ian Krop（Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment